Cerezyme® (imiglucerase) for injection logo

Gaucher Disease Type 1 Prevalence


Gaucher disease is a rare, progressive, genetic disorder that results in multi-organ dysfunction

Over 90% of patients are type 1, which can be effectively managed once diagnosed.1,2

Gaucher disease type 1 is more prevalent than you think

More than 90% of patients with Gaucher disease have type 1.2 Although Gaucher disease type 1 is a rare genetic condition, it’s important to understand its occurrence in different patient populations.

Estimated prevalence of Gaucher disease type 13,4

~1 in 50,000 to 1 in 100,000

Panethnic and occurs in ~1 in 50,000 to 1 in 100,000 in the general population

~1 in 500 to 1 in 1,000

More common in people of Ashkenazi Jewish heritage

~90%

of Jewish Americans are of Ashkenazi Jewish heritage

  • In patients of Ashkenazi Jewish heritage, the frequency of Gaucher disease has a higher incidence (~1 in 500 to 1 in 1,000) than hematologic malignancies (~1 in 2,500)2
  • In patients of Ashkenazi Jewish heritage, ~1 in 12 is a carrier5
  • Despite the high frequency of Gaucher disease among patients of Ashkenazi Jewish heritage, Gaucher disease type 1 is panethnic2

Gaucher disease type 1 is manageable once diagnosed

When an ERT is needed, choose the longest-approved therapy

An established ERT for children ages 2 and up

Studied in the largest reported group of pediatric patients with Gaucher disease type 1

ERT=enzyme replacement therapy.

Indication

Indication and Usage:

Cerezyme® (imiglucerase) for injection is indicated for treatment of adults and pediatric patients 2 years of age and older with Type 1 Gaucher disease that results in one or more of the following conditions:

  • anemia
  • thrombocytopenia
  • bone disease
  • hepatomegaly or splenomegaly

Important Safety Information

WARNING: HYPERSENSITIVITY REACTIONS INCLUDING ANAPHYLAXIS

Patients treated with enzyme replacement therapies have experienced life-threatening hypersensitivity reactions, including anaphylaxis. Anaphylaxis has occurred during the early course of enzyme replacement therapy and after extended duration of therapy.

Initiate CEREZYME in a healthcare setting with appropriate medical monitoring and support measures, including access to cardiopulmonary resuscitation equipment. If a severe hypersensitivity reaction (e.g., anaphylaxis) occurs, discontinue CEREZYME and immediately initiate appropriate medical treatment, including use of epinephrine. Inform patients of the symptoms of life-threatening hypersensitivity reactions, including anaphylaxis, and to seek immediate medical care should symptoms occur.

Warnings and Precautions:

Hypersensitivity Reactions Including Anaphylaxis: See Boxed WARNING.
Patients with antibody to imiglucerase have a higher risk of hypersensitivity reactions. Consider periodic monitoring during the first year of treatment for lgG antibody formation.

Consider risks and benefits of readministering Cerezyme to individual patients following a severe reaction. Consider reducing the rate of infusion, pretreat with antihistamines and/or corticosteroids, and monitor patients for new signs and symptoms of a severe hypersensitivity reaction.

Infusion-Associated Reactions:
Infusion associated reactions (IARs) have been observed in patients treated with Cerezyme. If an IAR occurs, decreasing the infusion rate, temporarily stopping the infusion and/or administering antihistamines and/or antipyretics may ameliorate the symptoms. Closely monitor patients who have experienced IARs when re-administering Cerezyme.

Adverse Reactions:
Adverse reactions reported in adults include back pain, chills, dizziness, fatigue, headache, hypersensitivity reactions, nausea, pyrexia, and vomiting.

Adverse reactions reported in pediatric patients 2 years of age and older are similar to adults.

Please see full Prescribing Information, including Boxed WARNING.

Indication

Important Safety Information

References: 1. Mistry PK, Sadan S, Yang R, Yee J, Yang M. Consequences of diagnostic delays in type 1 Gaucher disease: the need for greater awareness among hematologists-oncologists and an opportunity for early diagnosis and intervention. Am J Hematol. 2007;82(8):697-701. 2. Mistry PK, Cappellini MD, Lukina E, et al. A reappraisal of Gaucher disease-diagnosis and disease management algorithms. Am J Hematol. 2011;86(1):110-115. 3. Nalysnyk L et al. Hematology. 2017;22(2):65-73. 4. National Human Genome Institute. About Gaucher disease. National Institutes of Health. Updated January 4, 2012. Accessed August 2, 2025. www.genome.gov/Genetic-Disorders/Gaucher-Disease 5. Mistry PK, Weinthal JA, Weinreb NJ. Disease state awareness in Gaucher disease: a Q&A expert roundtable discussion. Clin Adv Hematol Oncol. 2012;10(6 Suppl 8):1-16.

© 2025 Sanofi. All rights reserved. Cerezyme and Sanofi are registered trademarks of Sanofi or an affiliate. MAT-US-2015574-v3.0-08/2025